News | January 03, 2022
U.S. FDA grants EUA for Pfizer-BioNTech booster for 12 years and older
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
First emergency use authorization in the United States for a Covid-19 vaccine booster in adolescents 12 through 15 years of age
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Rapid antigen testing provides results in just 15 minutes and the information can help reduce the risk of Covid-19 exposure
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The Covid-19 At-Home Test uses a simple nasal swab sample to enable individuals to self-test at home and receive accurate, reliable and quick results in as few as 20 minutes for SARS-CoV-2 and all known variants of concern, including Omicron
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Neutralising antibody levels against Omicron following a third dose boost of Vaxzevria were broadly similar to levels achieved after two doses against the Delta variant
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
Subscribe To Our Newsletter & Stay Updated
